NEW YORK, June 26, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Celgene Corporation (NASDAQ: CELG), Aetna Inc. (NYSE: AET), Theravance Inc. (NASDAQ: THRX) and MannKind Corporation (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Bristol-Myers Squibb Company Research Report
On June 20, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) and Otsuka America Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has approved an update to the product labeling of Sprycel (dasatinib). According to Bristol-Myers Squibb, the labeling now includes three-year efficacy and safety data in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), and five-year data in CP PH+ CML patients who are resistant or intolerant to Gleevec (imatinib mesylate). Information added to the label of Sprycel in the first-line CP Ph+ CML setting is based on three-year data from DASISION (Dasatinib versus Imatinib Study in Treatment-Naïve CML Patients). In the study, Sprycel showed superior efficacy as defined by higher molecular (major molecular responseor MMR) and confirmed cytogenetic response rates (CCyR3) by 12 months, compared to imatinib. Greg Stephens, Executive Director, National CML Society, said, "As patients continue to benefit from these treatments, understanding their safety and effectiveness over time becomes increasingly important and may help inform the decisions of healthcare providers as to which therapy they choose." The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/88a2_BMY]
--
Celgene Corporation Research Report
On June 17, 2013, Celgene International Sárl, a wholly owned subsidiary of Celgene Corporation (Celgene), announced that the European Commission (EC) has amended the marketing authorization for REVLIMID. With this amendment, REVLIMID has earned the approval to treat patients with transfusion-dependent anemia due to lower or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolate deletion 5q cytogenetic abnormality, when other therapeutic options are insufficient or inadequate. Dr. Aristotles Giagounidis, of the Marien Hospital in Dusseldorf, Germany, said, "Transfusion dependent MDS patients, with an isolated 5q deletion, have had few effective therapy options historically, but the European Commission decision now brings new hope for these people, with an effective and targeted treatment option. The standard of care for MDS has historically been red blood cell transfusions, which can help control the disease but pose a tremendous burden to patients - particularly the elderly, who make up the majority of MDS patients - as well as to health care providers and health systems." The Company said that REVLIMID will be launched by each EU country according to its local requirements. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/7541_CELG]
--
Aetna Inc. Research Report
On June 14, 2013, Aetna Inc. (Aetna) announced new leadership in its Government and International Businesses. Accordingly, the Company reported that Francis S. Soistman will lead the Aetna Government Services and Richard di Benedetto will join the Company as the head of Aetna International. Prior to this, Soistman led Aetna's Medicare business, helping oversee the Medicare components of the Coventry Health Care acquisition as well as the 2014 Medicare bids for Aetna and Coventry. On the other hand, Richard di Benedetto joins the Company from Euromedic International, one of the largest private medical services providers in Europe in the field of Diagnostics Services, Laboratories, and Cancer Treatment, where he served as the Chief Executive Officer. The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/c0ee_AET]
--
Theravance Inc. Research Report
On June 21, 2013, Theravance Inc. (Theravance) announced that the U.S. Food and Drug Administration (FDA) has approved VIBATIV (telavancin) for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. VIBATIV is the Company's bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action whereby telavancin both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. The Company plans to make VIBATIV available through wholesalers in Q3 2013 and is continuing to evaluate commercialization alternatives for the U.S. market. VIBATIV was approved in the U.S. in 2009 for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria (including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains). The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/f77e_THRX]
--
MannKind Corporation Research Report
On June 17, 2013, MannKind Corporation (MannKind) announced that all follow-up visits have been completed for the patients enrolled in Study 175, a Phase 3 clinical study of AFREZZA (insulin human [rDNA origin]) inhalation powder, an investigational rapid acting mealtime insulin therapy, administered using the Company's next generation inhaler. As per the Company, Study 175 assessed AFFREZZA by using the next-generation inhaler in patients with type 2 diabetes whose disease is inadequately controlled on metformin with or without second or third oral medication. MannKind will release data from the study of AFREZZA later in the summer of 2013. The Full Research Report on MannKind Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0b44_MNKD]
--
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports